Jonathan Stevenson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jonathan Stevenson has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- A. K. Stringer
A Department of Otolaryngology , The Royal Victorian Eye and Ear Hospital , 32 Gisborne St, East Melbourne 3002 , Victoria , Australia
1 shared publication Andrew Anglemyer
Health Intelligence Team, Institute of Environmental Science and Research, Wellington, New Zealand; Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
1 shared publicationBenjamin Chan
Department of Otolaryngology , Te Whatu Ora Te Toka Tumai , Auckland , New Zealand
1 shared publicationBenjamin James Thomson
1 shared publicationBenjamin Keren
Department of Surgery, Wellington Hospital, Wellington, New Zealand
1 shared publication- Daniel Stahlhoven1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Middle Ear Pseudogout: Case Report
Calcium pyrophosphate deposition disease (CPPD), also known as pseudogout, rarely affects the middle ear. We present a case of a 51-year-old male who presented with progressive unilateral hearing loss. Interval clinical examination demonstrated an enlarging white mass medial to the tympanic membrane with serial CT examinations revealing corresponding progressive opacification centred on the ossicular chain. The patient proceeded to a left tympanoplasty and ossiculoplasty during which a mass of solid white tissue was found to encase the malleus and incus. Subsequent histopathological assessment identified the presence of crystalline material consistent with calcium pyrophosphate, confirming adiagnosis of pseudogout.
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMiddle Ear Pseudogout: Case Report
Calcium pyrophosphate deposition disease (CPPD), also known as pseudogout, rarely affects the middle ear. We present a case of a 51-year-old male who presented with progressive unilateral hearing loss. Interval clinical examination demonstrated an enlarging white mass medial to the tympanic membrane with serial CT examinations revealing corresponding progressive opacification centred on the ossicular chain. The patient proceeded to a left tympanoplasty and ossiculoplasty during which a mass of solid white tissue was found to encase the malleus and incus. Subsequent histopathological assessment identified the presence of crystalline material consistent with calcium pyrophosphate, confirming adiagnosis of pseudogout.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Otolaryngology
- Vol. 2026 (1) , 9910461
Peptide Receptor Radionucleotide Therapy for Unresectable Paediatric Head and Neck Paraganglioma in Aotearoa New Zealand
Head and neck paragangliomas present incidentally or with signs of mass effect. Approximately 30%–40% are hereditary, which typically present at a younger age. Given their proximity to vital structures, they are often inoperable, and alternative treatment options have significant side effects. We present a case of a paediatric patient with a glomus jugulare paraganglioma who received peptide receptor radionucleotide therapy (PRRT), a targeted molecular therapy. We observed a good molecular response stable disease at 12‐month follow‐up and radiologically stable disease at 15 months posttreatment. PRRT is not currently a widely accessible treatment option, and the literature reports a reasonable disease response in treatment of head and neck paraganglioma.
- 1 January 2026
- Published by Wiley in Case Reports in Otolaryngology
- Vol. 2026 (1) , 9910461
Open AccessPeptide Receptor Radionucleotide Therapy for Unresectable Paediatric Head and Neck Paraganglioma in Aotearoa New Zealand
Head and neck paragangliomas present incidentally or with signs of mass effect. Approximately 30%–40% are hereditary, which typically present at a younger age. Given their proximity to vital structures, they are often inoperable, and alternative treatment options have significant side effects. We present a case of a paediatric patient with a glomus jugulare paraganglioma who received peptide receptor radionucleotide therapy (PRRT), a targeted molecular therapy. We observed a good molecular response stable disease at 12‐month follow‐up and radiologically stable disease at 15 months posttreatment. PRRT is not currently a widely accessible treatment option, and the literature reports a reasonable disease response in treatment of head and neck paraganglioma.
- 26 May 2025
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 195, 112407
The evolving epidemiology of paediatric acute mastoiditis in New Zealand
- 26 May 2025
- Published by Elsevier in International Journal of Pediatric Otorhinolaryngology
- Vol. 195, 112407
The evolving epidemiology of paediatric acute mastoiditis in New Zealand